Aliases & Classifications for Papilloma

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 55 15 73
Papillomatosis 12 55 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2615
MeSH 44 D010212
NCIt 50 C3713 C7440
SNOMED-CT 68 23730008 82049002

Summaries for Papilloma

Disease Ontology : 12 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to inverted papilloma and bladder transitional cell papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and testes, and related phenotypes are growth/size/body region and cellular

Wikipedia : 76 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 524)
# Related Disease Score Top Affiliating Genes
1 inverted papilloma 34.0 CDKN2A KRT13 KRT20 TP53
2 bladder transitional cell papilloma 33.7 CDKN1A TP53
3 frontal sinus inverted papilloma 33.6 KRT13 KRT5
4 inverted transitional papilloma 33.4 CDKN2A KRT5
5 anogenital venereal wart 32.4 CDKN2A TP53 UBE3A
6 urinary tract papillary transitional cell benign neoplasm 32.3 FGFR3 KRT20 TP53
7 li-fraumeni syndrome 31.9 CDKN1A CDKN2A PTEN TP53
8 palmoplantar keratoderma, epidermolytic 31.6 FLG KRT10 KRT14
9 keratosis, seborrheic 31.2 FGFR3 KRT10 KRT5
10 suppressor of tumorigenicity 3 30.6 CDKN1A CDKN2A RB1 TP53 UBE3A
11 oral cancer 30.6 CDKN2A KRT13 TP53
12 squamous cell carcinoma 30.6 CDKN2A FGFR3 IVL PTEN RB1 TP53
13 oropharynx cancer 30.6 CDKN2A KRT14 KRT5 TP53
14 verrucous carcinoma 30.5 CDKN2A KRT10 RB1 TP53
15 in situ carcinoma 30.5 CDKN2A KRT14 KRT5 TP53
16 larynx cancer 30.4 CDKN2A PTEN TP53
17 cholangiocarcinoma 30.4 KRT20 KRT8 PTEN TP53
18 adenocarcinoma 30.3 CDKN2A FGFR3 PTEN RB1 TP53
19 retinoblastoma 30.3 CDKN1A CDKN2A RB1 TP53
20 cervical cancer 30.3 CDKN1A CDKN2A FGFR3 KRT14 KRT5 PTEN
21 gastric adenocarcinoma 30.2 CDKN2A CDKN2B KRT20 KRT8 PTEN TP53
22 lymphoepithelioma-like carcinoma 30.2 KRT20 KRT5 KRT8
23 ductal carcinoma in situ 30.2 KRT14 KRT5 KRT8 TP53
24 transitional cell carcinoma 30.2 CDKN2A FGFR3 KRT20 KRT8 PTEN TP53
25 keratoacanthoma 30.1 CDKN1A FLG KRT10 TP53
26 bowenoid papulosis 30.1 CDKN2A FLG
27 squamous cell carcinoma, head and neck 30.0 CDKN1A CDKN2A FGFR3 PTEN RB1 TP53
28 bladder urothelial carcinoma 30.0 FGFR3 KRT20 RB1 TP53
29 bladder cancer 30.0 CDKN1A CDKN2A FGFR3 KRT20 RB1 TP53
30 bladder squamous cell carcinoma 29.9 CDKN2A TP53
31 cervical squamous cell carcinoma 29.9 CDKN2A KRT8 TP53
32 non-invasive bladder papillary urothelial neoplasm 29.9 FGFR3 TP53
33 tongue cancer 29.9 CDKN1A CDKN2A KRT13 TP53
34 basaloid squamous cell carcinoma 29.9 CDKN2A KRT13 KRT14 KRT8 TP53
35 esophageal cancer 29.9 CDKN1A CDKN2A CDKN2B FSCN1 PTEN RB1
36 endocervical adenocarcinoma 29.9 CDKN2A KRT20 TP53
37 nasal cavity squamous cell carcinoma 29.8 CDKN2A KRT5 KRT8
38 cervical adenocarcinoma 29.8 CDKN1A CDKN2A KRT20 TP53
39 adenosquamous carcinoma 29.8 KRT5 KRT8 TP53
40 actinic keratosis 29.8 CDKN2A FLG KRT20 TP53
41 lichen planus 29.7 FLG IVL KRT10 KRT13 TP53
42 cervix carcinoma 29.7 CDKN2A FGFR3 TP53
43 small cell cancer of the lung 29.6 CDKN2A KRT20 PTEN RB1 TP53
44 glioblastoma 29.6 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
45 giant cell glioblastoma 29.6 FGFR3 PTEN TP53
46 lung cancer 29.6 CDKN1A CDKN2A CDKN2B FGFR3 KRT20 PTEN
47 large cell acanthoma 29.4 KRT10 KRT14 KRT5
48 gastric cancer 29.4 CDKN1A CDKN2A CDKN2B KRT20 PTEN TP53
49 lung cancer susceptibility 3 29.4 CDKN1A CDKN2A FGFR3 KRT20 TP53
50 keratosis 29.3 FGFR3 FLG IVL KRT10

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

MGI Mouse Phenotypes related to Papilloma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 AMOT CDKN1A CDKN2A FGFR3 FSCN1 KRT14
2 cellular MP:0005384 10.25 AMOT CDKN1A CDKN2A CDKN2B FGFR3 FSCN1
3 mortality/aging MP:0010768 10.21 AMOT CDKN1A CDKN2A CDKN2B FGFR3 FSCN1
4 digestive/alimentary MP:0005381 10.15 CDKN1A CDKN2A FGFR3 KRT14 KRT5 KRT8
5 embryo MP:0005380 10.13 AMOT CDKN1A CDKN2A FSCN1 KRT8 PTEN
6 integument MP:0010771 10.1 CDKN1A CDKN2A CDKN2B FGFR3 KRT14 KRT5
7 neoplasm MP:0002006 9.92 CDKN1A CDKN2A CDKN2B FGFR3 KRT14 PTEN
8 hearing/vestibular/ear MP:0005377 9.91 CDKN1A FGFR3 KRT14 KRT8 RB1 TP53
9 no phenotypic analysis MP:0003012 9.86 CDKN1A CDKN2A CDKN2B FGFR3 KRT5 RB1
10 reproductive system MP:0005389 9.65 CDKN1A CDKN2A CDKN2B FGFR3 KRT14 KRT8
11 pigmentation MP:0001186 9.55 CDKN2A KRT14 PTEN RB1 TP53
12 respiratory system MP:0005388 9.17 CDKN1A CDKN2A FGFR3 KRT14 PTEN RB1

Drugs & Therapeutics for Papilloma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
2
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
3
Tafinlar 18 49 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
4
Zelboraf 18 49 VEMURAFENIB Roche August of 2011

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 262)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cidofovir Approved Phase 4,Phase 2,Phase 1 113852-37-2 60613
2
Polihexanide Approved, Investigational Phase 4 28757-47-3
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
4
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
5
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Chlorhexidine gluconate Phase 4
15 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Biguanides Phase 4
17 Anti-Infective Agents, Local Phase 4
18 Disinfectants Phase 4
19 Hypoglycemic Agents Phase 4
20 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
21 MF59 oil emulsion Phase 4
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
23 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Interferon Inducers Phase 4,Phase 2,Phase 3,Phase 1
25 interferons Phase 4,Phase 2,Phase 3,Phase 1
26 Insulin, Globin Zinc Phase 4,Phase 3
27 insulin Phase 4,Phase 3
28
Azithromycin Approved Phase 3,Not Applicable 83905-01-5 55185 447043
29
Cetuximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 205923-56-4 56842117 2333
30
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
31 tannic acid Approved Phase 3
32
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
34
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
35
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
36
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
37
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
38
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
39
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
40
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
41
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
42
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
43
Zinc Approved, Investigational Phase 3,Not Applicable 7440-66-6
44
Zinc sulfate Approved, Investigational Phase 3,Not Applicable 7733-02-0
45 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
46
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 388082-78-8, 231277-92-2 208908 9941095
47 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
49 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
50 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 419)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Use of Cidofovir for Recurrent Respiratory Papillomatosis Completed NCT00205374 Phase 4 Cidofovir;Placebo
4 A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men Completed NCT01431079 Phase 4
5 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
6 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
7 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
8 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
9 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
10 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
11 Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) Recruiting NCT03391921 Phase 4
12 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
13 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
14 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
15 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
16 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
17 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
18 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
19 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
20 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
21 Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine Completed NCT00316706 Phase 3
22 Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. Completed NCT00196924 Phase 3
23 Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 Completed NCT00169494 Phase 3
24 Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Completed NCT00380367 Phase 3
25 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
26 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Completed NCT00196937 Phase 3
27 Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) Completed NCT01862874 Phase 3
28 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
29 A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) Completed NCT02114385 Phase 3
30 Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
31 Safety and Tolerability Study of V501 in Japanese Boys (V501-200) Completed NCT02576054 Phase 3
32 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
33 Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Completed NCT00345878 Phase 3
34 Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women Completed NCT00344032 Phase 3
35 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
36 Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Completed NCT00157950 Phase 3
37 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects Completed NCT00578227 Phase 3
38 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years Completed NCT00485732 Phase 3
39 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
40 Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls Completed NCT01381575 Phase 3
41 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age Completed NCT00552279 Phase 3
42 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
43 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
44 A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). Completed NCT01254643 Phase 3
45 Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Completed NCT01955252 Phase 3 Azithromycin
46 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
47 Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age Completed NCT00492544 Phase 3
48 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Completed NCT00456807 Phase 3
49 A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls Completed NCT02562508 Phase 3
50 A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Papilloma

Anatomical Context for Papilloma

MalaCards organs/tissues related to Papilloma:

41
Skin, Lung, Testes, Cervix, Bone, T Cells, Breast

Publications for Papilloma

Articles related to Papilloma:

(show top 50) (show all 2877)
# Title Authors Year
1
A 17-year-old woman with a solitary, mixed squamous cell and glandular papilloma of the bronchus. ( 30519472 )
2019
2
Posterior fossa choroid plexus papilloma with focal ependymal differentiation in an adult patient: A case report and literature review. ( 30546813 )
2019
3
Human papillomavirus types causing recurrent respiratory papillomatosis in Zimbabwe. ( 30554686 )
2019
4
Clinical features of nasal and sinonasal inverted papilloma associated with malignancy. ( 29548524 )
2018
5
Malignant Transformation of a Canine Papillomavirus Type 1-Induced Persistent Oral Papilloma in a 3-Year-Old Dog. ( 29865982 )
2018
6
Degenerated Keratinized Tumor Cells in Oropharyngeal Human Papilloma Virus-Associated Squamous Cell Carcinoma: A Pitfall in p16 Immunostaining of Fine-Needle Aspiration Specimens. ( 29966127 )
2018
7
Human Papilloma Virus and Autophagy. ( 29914057 )
2018
8
Genotype patterns and prevalence of human papilloma virus in non-vaccinated women in Zunyi, China. ( 29915851 )
2018
9
Human Papilloma Virus 16/18: Fabricator of Trouble in Oral Squamous Cell Carcinoma. ( 29432879 )
2018
10
Prognostic Significance of Human Papilloma Virus and p16 Expression in Patients with Vulvar Squamous Cell Carcinoma who Received Radiotherapy. ( 29449057 )
2018
11
Assessing the performance of a Loop Mediated Isothermal Amplification (LAMP) assay for the detection and subtyping of high-risk suptypes of Human Papilloma Virus (HPV) for Oropharyngeal Squamous Cell Carcinoma (OPSCC) without DNA purification. ( 29422018 )
2018
12
Human papilloma virus-specific T cells can be generated from naA^ve T cells for use as an immunotherapeutic strategy for immunocompromised patients. ( 29331266 )
2018
13
Improving human papilloma virus vaccination rates throughout military treatment facilities. ( 29433899 )
2018
14
Intraductal papilloma arising from the accessory parotid gland: A case report and literature review. ( 29768362 )
2018
15
Laryngeal squamous cell papilloma is highly associated with human papillomavirus. ( 29447361 )
2018
16
Detection of urinary Chlamydia trachomatis, Mycoplasma genitalium and human papilloma virus in the first trimester of pregnancy by PCR method. ( 29866110 )
2018
17
DNA fragmentation index and human papilloma virus in males with previous assisted reproductive technology failures. ( 29975635 )
2018
18
Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. ( 29969771 )
2018
19
Detection of Epstein-Barr and Human Papilloma Viruses in the Middle Ear Squamous Cell Carcinoma. ( 29456946 )
2018
20
Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review. ( 29333935 )
2018
21
Amyotrophic Lateral Sclerosis after Receiving the Human Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl. ( 29434138 )
2018
22
Mammographic and ultrasound findings in poroid hidradenoma of the breast mimicking intraductal papilloma and papillary carcinoma: A case report. ( 29924021 )
2018
23
Better surgical outcome by image-guided navigation system in endoscopic removal of sinonasal inverted papilloma. ( 29678350 )
2018
24
A unique presentation of an adolescent with disseminated atypical choroid plexus papilloma. ( 29770898 )
2018
25
Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing. ( 29779136 )
2018
26
Knowledge And Perception Of Female Nursing Students About Human Papilloma Virus (Hpv), Cervical Cancer And Attitudes Towards Hpv Vaccination. ( 29979917 )
2018
27
Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). ( 29393378 )
2018
28
Oncocytic Schneiderian papilloma-associated adenocarcinoma and KRAS mutation: A case report. ( 29879069 )
2018
29
Human Papilloma Virus and the Nurse's Role in Education and Prevention. ( 29905584 )
2018
30
Human Papilloma Virus (HPV) self-sampling: do women accept it? ( 29385850 )
2018
31
Management of Inverted Papilloma During Holmium Laser Enucleation of the Prostate. ( 29545053 )
2018
32
Poor Knowledge of Human Papilloma Virus and Vaccination Among Respondents from Three Nigerian States. ( 29922993 )
2018
33
A Tale of Two Tumors: a Case of Concomitant Esophageal Squamous Papilloma and Granular Cell Tumor. ( 29453760 )
2018
34
Optical coherence tomography and confocal laser scanning microscopy as non-invasive tools in the diagnosis of sinonasal inverted papilloma: a pilot study. ( 29737509 )
2018
35
Raman Spectroscopy for Inverted Papilloma: A Proof-of-Concept Study. ( 29763337 )
2018
36
Knowledge, Decision-Making and Acceptance of Human Papilloma Virus Vaccination among Parents of Primary School Students in Kota Bharu, Kelantan, Malaysia ( 29936724 )
2018
37
Endoscopic mucosal resection of rectal squamous cell papilloma. ( 29351698 )
2018
38
Atypical Presentation of Squamous Papilloma. ( 29342034 )
2018
39
Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV). ( 29404275 )
2018
40
A unique case of a huge mixed squamous cell and glandular papilloma of non-endobronchial origin with a peripheral growth. ( 29977775 )
2018
41
Use of intraoperative negative margins reduces inverted papilloma recurrence. ( 29336292 )
2018
42
Human papillomavirus: An unlikely etiologic factor in sinonasal inverted papilloma. ( 29668071 )
2018
43
Analysis of miRNA expression profiling identifies miR-214-3p as a novel biomarker in sinonasal inverted papilloma. ( 29952653 )
2018
44
Benign inverted papilloma at bladder neck causing acute urinary retention. ( 29942474 )
2018
45
Advancements in electrochemical DNA sensor for detection of human papilloma virus? A review. ( 29981317 )
2018
46
Management of intraductal papilloma without atypia of the breast diagnosed on core biopsy: Size and sampling matter. ( 29687535 )
2018
47
Benign Intraductal Papilloma without Atypia on Core Needle Biopsy Has a Low Rate of Upgrading to Malignancy after Excision. ( 29628987 )
2018
48
Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection: A systematic review and meta-analysis of randomized clinical trials. ( 29794788 )
2018
49
Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention. ( 29368102 )
2018
50
Survivin and cortactin expression in sinonasal schneiderian (inverted) papilloma and associated carcinoma. ( 29644904 )
2018

Variations for Papilloma

Expression for Papilloma

Search GEO for disease gene expression data for Papilloma.

Pathways for Papilloma

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 FGFR3 FLG IVL KRT10 KRT13 KRT14
2
Show member pathways
12.98 CDKN1A FGFR3 PTEN RB1 TP53 UBE3A
3
Show member pathways
12.83 CDKN1A CDKN2A PTEN RB1 TP53
4 12.79 CDKN1A CDKN2A CDKN2B FGFR3 PTEN RB1
5
Show member pathways
12.75 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
6
Show member pathways
12.69 CDKN1A CDKN2A CDKN2B FGFR3 PTEN RB1
7
Show member pathways
12.57 CDKN1A CDKN2A CDKN2B RB1 TP53
8 12.46 CDKN1A CDKN2A RB1 TP53
9 12.46 CDKN1A CDKN2A FGFR3 FSCN1 PTEN TP53
10 12.42 CDKN1A CDKN2A CDKN2B RB1 TP53
11
Show member pathways
12.39 CDKN1A CDKN2A CDKN2B RB1
12
Show member pathways
12.37 CDKN1A CDKN2A PTEN RB1 TP53
13 12.36 CDKN1A CDKN2A CDKN2B RB1 TP53
14
Show member pathways
12.32 CDKN1A CDKN2A CDKN2B RB1 TP53
15 12.29 AMOT FSCN1 KRT10 KRT13 KRT20 KRT5
16
Show member pathways
12.23 CDKN1A PTEN RB1 TP53
17
Show member pathways
12.22 CDKN1A FGFR3 PTEN RB1 TP53
18
Show member pathways
12.21 CDKN1A CDKN2A CDKN2B RB1
19 12.15 CDKN1A CDKN2A CDKN2B RB1 TP53 UBE3A
20 12.12 CDKN1A FGFR3 PTEN TP53
21 12.07 CDKN1A PTEN RB1 TP53
22 12.03 CDKN1A CDKN2A RB1 TP53 UBE3A
23 12 CDKN1A CDKN2A PTEN TP53
24
Show member pathways
11.96 KRT13 KRT14 KRT5 KRT8
25 11.9 CDKN1A CDKN2A PTEN RB1 TP53
26 11.86 CDKN1A CDKN2A PTEN RB1 TP53
27 11.85 CDKN1A PTEN RB1 UBE3A
28 11.84 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
29 11.81 CDKN1A RB1 TP53
30 11.77 CDKN1A KRT14 KRT5 TP53
31 11.77 CDKN1A CDKN2B PTEN RB1 TP53
32 11.72 CDKN1A CDKN2A TP53
33
Show member pathways
11.68 FLG IVL KRT10 KRT13 KRT14 KRT20
34 11.67 CDKN1A CDKN2A RB1 TP53 UBE3A
35 11.66 FGFR3 PTEN TP53
36 11.58 CDKN1A CDKN2A FGFR3 RB1 TP53
37 11.5 CDKN1A CDKN2A RB1 TP53
38 11.32 CDKN2A CDKN2B TP53
39 11.1 CDKN2A RB1 TP53
40
Show member pathways
11.09 CDKN1A CDKN2A TP53
41 11.02 CDKN1A CDKN2B PTEN RB1 TP53
42 10.76 CDKN1A TP53
43
Show member pathways
10.58 CDKN1A TP53

GO Terms for Papilloma

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.89 AMOT CDKN1A CDKN2A CDKN2B FLG FSCN1
2 PML body GO:0016605 9.58 PTEN RB1 TP53
3 keratin filament GO:0045095 9.56 KRT13 KRT14 KRT5 KRT8
4 cornified envelope GO:0001533 9.54 FLG IVL KRT10
5 intermediate filament GO:0005882 9.17 FLG KRT10 KRT13 KRT14 KRT20 KRT5
6 cytoplasm GO:0005737 10.2 CDKN1A CDKN2A CDKN2B FGFR3 FSCN1 IVL
7 nucleus GO:0005634 10.06 AMOT CDKN1A CDKN2A CDKN2B FGFR3 FLG

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
2 G1/S transition of mitotic cell cycle GO:0000082 9.77 CDKN1A CDKN2A RB1
3 keratinocyte differentiation GO:0030216 9.73 FLG IVL KRT10
4 negative regulation of epithelial cell proliferation GO:0050680 9.72 CDKN2B PTEN RB1
5 Ras protein signal transduction GO:0007265 9.71 CDKN1A CDKN2A RB1 TP53
6 peptide cross-linking GO:0018149 9.69 FLG IVL KRT10
7 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.67 CDKN1A CDKN2B PTEN
8 cell cycle arrest GO:0007050 9.65 CDKN1A CDKN2A CDKN2B RB1 TP53
9 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.62 CDKN1A CDKN2B PTEN RB1
10 negative regulation of phosphorylation GO:0042326 9.61 CDKN1A CDKN2A CDKN2B
11 hemidesmosome assembly GO:0031581 9.58 KRT14 KRT5
12 response to arsenic-containing substance GO:0046685 9.58 CDKN1A PTEN
13 hepatocyte apoptotic process GO:0097284 9.57 KRT8 RB1
14 prostate gland growth GO:0060736 9.54 PTEN UBE3A
15 replicative senescence GO:0090399 9.54 CDKN1A CDKN2A TP53
16 keratinization GO:0031424 9.5 IVL KRT10 KRT13 KRT14 KRT20 KRT5
17 signal transduction by p53 class mediator GO:0072331 9.48 CDKN1A TP53
18 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.33 CDKN2A CDKN2B PTEN
19 cornification GO:0070268 9.23 FLG IVL KRT10 KRT13 KRT14 KRT20
20 apoptotic process GO:0006915 10 CDKN2A FGFR3 KRT20 PTEN RB1 TP53

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 CDKN1A CDKN2A CDKN2B PTEN TP53
2 ubiquitin protein ligase binding GO:0031625 9.67 CDKN1A RB1 TP53 UBE2L3
3 structural constituent of cytoskeleton GO:0005200 9.61 KRT14 KRT20 KRT5
4 disordered domain specific binding GO:0097718 9.43 CDKN2A RB1 TP53
5 structural constituent of epidermis GO:0030280 9.4 FLG KRT10
6 structural molecule activity GO:0005198 9.35 FLG IVL KRT10 KRT13 KRT8
7 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN1A CDKN2A CDKN2B
8 protein binding GO:0005515 10.11 AMOT CDKN1A CDKN2A CDKN2B FGFR3 FLG

Sources for Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....